Health Experts Advocate for Comprehensive Dengue Prevention Strategy in Indonesia as Disease Shifts from Seasonal to Year-Round Threat

The landscape of public health in Indonesia is facing a significant paradigm shift as medical experts and researchers warn that Dengue Hemorrhagic Fever (DHF) can no longer be categorized as a seasonal ailment. Traditionally associated with the onset of the monsoon season, the risk of dengue transmission in the Indonesian archipelago has evolved into a perennial threat, necessitating a move away from reactive, seasonal interventions toward a sustained, year-round comprehensive prevention strategy. This urgency comes amid rising case numbers and a staggering economic burden that impacts both the national healthcare system and individual household stability.

For decades, the Indonesian government and public health agencies have relied heavily on the "3M Plus" campaign—which involves Menguras (draining water containers), Menutup (covering water storage), and Mendaur ulang (recycling potential breeding sites), plus additional measures like using mosquito nets and repellent. However, at the 9th Asia Dengue Summit held in Singapore, specialists argued that while these vector control methods remain foundational, they are no longer sufficient to curb the spread of the virus in an era characterized by rapid urbanization and fluctuating climate patterns.

The Shift to a Comprehensive Prevention Framework

Professor Sri Rezeki Hadinegoro, a prominent figure from the Faculty of Medicine at the University of Indonesia (FKUI), emphasizes that the complexity of the dengue virus requires a multi-faceted defense. According to Professor Sri, the conventional reliance on one or two methods is inadequate against a disease that is becoming increasingly pervasive. She advocates for an integrated strategy that harmonizes three critical pillars: rigorous vector control, enhanced clinical diagnosis at the primary healthcare level, and the widespread adoption of medical innovations, specifically vaccination.

"Facing the threat of dengue, which is so severe and widespread, we can no longer rely solely on one or two conventional prevention efforts like 3M Plus. We need something comprehensive," Professor Sri stated. She further elaborated that protecting the most vulnerable populations, particularly children, requires a "shield" built from both environmental management and biological immunity. This comprehensive approach is designed to close the gaps left by traditional mosquito eradication programs, which often struggle with consistency and public compliance.

The Staggering Economic Toll of Dengue

The call for a revamped strategy is backed by sobering data regarding the socio-economic impact of the disease. A comprehensive study conducted by Universitas Gadjah Mada (UGM) projected that by 2024, the total economic burden of dengue in Indonesia would reach approximately USD 550.9 million, or nearly Rp9 trillion. This figure encompasses direct medical costs, such as hospital stays and medications, as well as indirect costs, including lost productivity for patients and caregivers.

The UGM study further estimated that the disease would result in more than 2 million hospitalizations annually across the country. These statistics highlight that dengue is not merely a clinical issue but a significant hurdle to Indonesia’s national development and economic resilience. When a family member is hospitalized with dengue, the financial shock can be devastating, often leading to "catastrophic spending" that can push lower-income families into poverty.

Vaccination as a Pillar of Long-Term Control

One of the most significant advancements discussed by experts is the integration of dengue vaccines into the national health framework. Professor Jarir At Thobari, from the Department of Pharmacology and Therapy, presented an economic modeling study at the 9th Asia Dengue Summit that illustrates the long-term benefits of vaccination. The modeling suggests that a consistent implementation of dengue vaccination over a 20-year period could drastically alter the disease’s trajectory in Indonesia.

According to the projections, vaccination could prevent between 1.1 million and 1.3 million Disability-Adjusted Life Years (DALYs). The DALY is a critical metric used by the World Health Organization (WHO) to quantify the burden of disease, representing the number of years lost due to ill-health, disability, or early death. By reducing the DALY count, vaccination not only saves lives but ensures that more citizens remain healthy and productive contributors to society.

From a fiscal perspective, the modeling indicates that a 20-year vaccination program could yield cost savings ranging from USD 329 million to USD 731 million (approximately Rp5.2 trillion to Rp11.5 trillion). These savings stem from the reduction in symptomatic cases, fewer emergency room visits, and a decrease in the occupancy of hospital beds, which allows healthcare resources to be allocated to other pressing medical needs.

Protecting the Next Generation: A Pediatric Perspective

The vulnerability of children remains a primary concern for medical professionals. Dr. Rismala Dewi, Chairperson of the Indonesian Pediatric Society (IDAI) for the Jakarta Chapter, pointed out that children often suffer the most severe complications from dengue. Because their immune systems are still developing, the progression from a standard fever to dengue shock syndrome can occur rapidly, sometimes within hours.

"Dengue remains a health challenge that we must face together," Dr. Rismala noted. "Pediatricians play a vital role in educating parents, encouraging early detection, and helping families understand various protective steps to reduce the risk and impact of dengue on children."

The IDAI has been proactive in updating clinical guidelines to ensure that doctors across the country can identify early warning signs, such as persistent vomiting, mucosal bleeding, or extreme lethargy, which indicate that a case is becoming critical. However, Dr. Rismala stresses that prevention through vaccination and environmental control is far more effective than treatment after a child has already become ill.

Corporate Social Responsibility and Public-Private Partnerships

The push for a dengue-free Indonesia is also seeing increased involvement from the private sector. PT Takeda Innovative Medicines has emerged as a key partner in this mission, working alongside the government, healthcare professional organizations, and educational institutions. Their efforts focus on "Dengue Travel" education campaigns and expanding access to innovative prevention tools.

Andreas Gutknecht, President Director of PT Takeda Innovative Medicines, emphasized that every individual in Indonesia is at risk of infection, regardless of their socio-economic status or geographic location. "We remain committed to working with various stakeholders to support comprehensive dengue prevention efforts through continuous education and expanding access to innovative prevention," Gutknecht said. The goal is to empower families to take proactive steps before an outbreak occurs, rather than reacting to one.

Analyzing the Broader Implications: Climate and Urbanization

The transition of dengue into a year-round threat is closely linked to broader environmental trends. Climate change has led to warmer average temperatures and unpredictable rainfall patterns in Indonesia, creating ideal breeding conditions for the Aedes aegypti mosquito throughout the year. Furthermore, rapid urbanization has resulted in high-density living environments where water storage is common, providing ample opportunities for mosquitoes to thrive in close proximity to human hosts.

The shift toward a comprehensive strategy also reflects a global trend in tropical medicine. Countries like Brazil and Thailand have also begun integrating vaccination with high-tech mosquito control methods, such as the release of Wolbachia-infected mosquitoes, which are unable to transmit the virus. In Indonesia, the "Wolbachia" technology has already seen successful trials in Yogyakarta and is being expanded to other cities like Bandung and Jakarta.

Conclusion: A Call for Sustained Action

The evidence presented by health experts, economists, and pharmaceutical leaders converges on a single point: the old methods of fighting dengue are no longer sufficient for the modern challenges Indonesia faces. The path forward requires a synergy of traditional hygiene (3M Plus), biological intervention (vaccination), and technological innovation (Wolbachia and digital surveillance).

As Indonesia looks toward its future health goals, the integration of these strategies offers a viable roadmap to significantly reduce the morbidity and mortality associated with dengue. The transition from a seasonal "emergency" mindset to a permanent, comprehensive prevention culture is not just a medical necessity—it is an economic and social imperative to protect the health and prosperity of the nation’s 278 million citizens. The potential to save trillions of rupiah and, more importantly, millions of "healthy years" of life, makes the adoption of this comprehensive strategy one of the most critical public health priorities of the decade.